EW vs OMCL: fair value comparison
Edwards Lifesciences Corporation and Omnicell, Inc. · Updated 2026-10-19
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, EW currently sits closer to the top of our ranking by discount to fair value. EW carries the stronger quality grade.
| EW | OMCL | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $85.21 | $35.39 |
| 12-month range | $75.87–$95.18 | $29.57–$51.39 |
| Rank by discount to fair value | #33 of 108 Healthcare | #36 of 108 Healthcare |
| Quality grade | A | B |
| Leverage | Low | Low |
| Margin trend | Stable | Stable |
| Revenue growth | Strong | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | — | Mixed |
| DCF cross-check | Overvalued | Fairly Valued |
| 52-week position | The lower-middle quarter | The lower-middle quarter |
Full single-stock breakdowns: EW fair value analysis · OMCL fair value analysis